Patients visiting Elect Dermatology for brown patches, uneven skin tone, or dark spots often arrive having already tried products marketed for “hyperpigmentation” — sometimes for months — without meaningful improvement. In many cases, the issue is a diagnostic mismatch: melasma and general hyperpigmentation look similar on the surface but have distinct causes, distinct depth patterns, and different optimal treatments. Understanding which condition you have is the starting point for melasma and hyperpigmentation treatment in New Braunfels.
What Is Melasma?
Melasma is a chronic pigmentation disorder characterized by symmetric, irregular brown to gray-brown patches on the face — most commonly on the cheeks, forehead, bridge of the nose, chin, and upper lip. It results from a complex interaction between UV exposure, hormonal factors (estrogen, progesterone), and genetic predisposition. Melasma is significantly more prevalent in women and in individuals with Fitzpatrick skin types III–VI, though it can occur in men and lighter skin types.
A comprehensive review by Sheth and Pandya (J Am Acad Dermatol, 2011) established melasma as a multifactorial condition in which UV light stimulates melanocytes to overproduce melanin, hormones act as sensitizers and co-triggers, and epidermal and dermal components are involved. This multi-layer involvement (epidermal, dermal, or mixed) partly explains why melasma is more treatment-resistant than superficial pigmentation disorders.
Melasma is associated with pregnancy (historically called “chloasma” or the “pregnancy mask”), oral contraceptives, and hormone replacement therapy. It often improves postpartum or after discontinuing hormonal contraceptives, though it can persist or recur without careful sun protection.
What Is Hyperpigmentation?
Hyperpigmentation is a broad descriptive term for any skin darkening caused by excess melanin deposition. It encompasses several distinct conditions with different mechanisms:
Post-inflammatory hyperpigmentation (PIH) develops after skin inflammation — acne, eczema, psoriasis, chemical exposure, or any injury that activates inflammatory melanocytes. PIH results from melanin released during the inflammatory cascade and deposited in the epidermis or dermis. It is especially pronounced and longer-lasting in darker skin tones (Fitzpatrick IV–VI). Unlike melasma, PIH is not hormonally driven and follows the pattern of prior inflammatory events rather than characteristic facial zones.
Solar lentigines (age spots / sun spots) are discrete, well-demarcated flat spots caused by decades of cumulative UV exposure stimulating localized melanocyte proliferation. They appear on chronically sun-exposed areas: face, dorsal hands, forearms, neck, and chest. They are not hormonally triggered, and they respond to consistent sun protection plus topical and peel-based treatment.
Freckles (ephelides) reflect localized melanin clusters with a hereditary component, worsening with UV exposure. They require treatment only when the patient desires cosmetic improvement.
How Melasma and Hyperpigmentation Differ
The key clinical distinctions that guide diagnosis:
Pattern: Melasma produces symmetric, confluent patches in characteristic facial zones. PIH follows the distribution of prior inflammatory events — acne scars on the chin and cheeks, for example. Solar lentigines are discrete, scattered spots on sun-exposed areas.
Triggers: Melasma is triggered by UV plus hormonal factors. PIH requires a prior inflammatory event. Solar lentigines require cumulative UV exposure only, with no hormonal component.
Depth: Melasma can be epidermal, dermal, or mixed — dermoscopy and Wood’s lamp examination help characterize depth. Epidermal melasma responds better to topical treatment; dermal melasma is more resistant. PIH from superficial inflammation is typically epidermal; PIH from deeper dermal inflammation deposits pigment in the dermis and takes longer to fade.
Prognosis: Solar lentigines and superficial PIH have the most predictable treatment responses. Melasma can be significantly improved but is chronic and prone to recurrence without strict ongoing photoprotection and maintenance therapy. Dermal PIH may take 1–2 years to fully fade even with treatment.
Treatment by Condition
Melasma: First-line treatment combines a tyrosinase inhibitor (prescription hydroquinone 4%, or tranexamic acid for patients who cannot tolerate hydroquinone), a retinoid (tretinoin accelerates epidermal turnover and disperses melanin), and a mild topical corticosteroid (the Kligman formula). Strict broad-spectrum SPF 50+ sunscreen — preferably with iron oxide to also block visible light — is non-negotiable and constitutes first-line therapy in itself. Chemical peels can augment topical therapy, but aggressive peeling in melasma-prone skin risks PIH as a complication. Laser treatment must be selected carefully — some devices can paradoxically worsen melasma. Per the AAD, melasma requires long-term management with realistic expectations.
Post-inflammatory hyperpigmentation: Addressing the underlying inflammatory condition is the first step — uncontrolled acne continues to generate new PIH as fast as old marks fade. Topical retinoids accelerate epidermal pigment clearance. Azelaic acid has anti-inflammatory and mild depigmenting properties useful for PIH, particularly in sensitive or reactive skin. Chemical peels with glycolic or salicylic acid are effective for superficial PIH. A review of post-inflammatory hyperpigmentation in skin of color makes the same point. For stubborn epidermal PIH we lean on prescription topicals and superficial peels, with extra caution in darker skin tones, where aggressive treatment can trigger more pigment rather than less.
Solar lentigines: At Elect Dermatology we treat these with topical retinoids and chemical peels, which fade them gradually, alongside daily sun protection to keep new ones from forming.
Why Accurate Diagnosis Changes Outcomes
A patient with dermal melasma using a brightening serum designed for PIH may see no meaningful improvement and conclude that nothing works for their skin — when in fact the formulation never had a mechanism to reach the dermal pigment. Conversely, aggressive laser treatment used for solar lentigines applied to melasma skin risks a significant worsening. The clinical distinction matters in both directions. Dermoscopy at Elect Dermatology helps characterize lesion depth and pattern to direct treatment precisely.
Brown patches, dark spots, or uneven skin tone that isn’t responding to over-the-counter products may reflect an accurate diagnosis problem, not a treatment failure. The board-certified dermatologists at Elect Dermatology in New Braunfels use clinical examination and dermoscopy to distinguish between melasma, post-inflammatory hyperpigmentation, solar lentigines, and other pigmentation disorders — and build a treatment plan matched precisely to your condition. Call (833) 353-2875 at 2154 Gabriels Pl, Ste 103, New Braunfels, TX 78130.
Reviewed by Dr. Stahr
Schedule Your Dermatology Appointment
Our board certified dermatologists in New Braunfels are here to help. New patients are always welcome.
